Johnson & Johnson’s TECNIS PureSee^™ IOL^* Wins 2025 MedTech Breakthrough Award!

Johnson & Johnson^† has been awarded the 2025 MedTech Breakthrough Award for its TECNIS PureSee^™ IOL^*, a technology-driven innovation in intraocular lenses (IOLs). This award, recognizing the “Best New Technology Solution – Ophthalmology,” underscores the innovative contributions of Johnson & Johnson in advancing vision correction in cataract surgery. 

Cataract surgery is the number one surgery performed globally, with 28 million procedures each year. But only 10-15% of patients are getting advanced optical IOLs specifically designed for astigmatism and presbyopia.¹ The TECNIS PureSee^™ IOL seeks to change this by offering a purely refractive presbyopia-correcting design, now available in EMEA, APAC, Canada, and Latin America, with plans for further global expansion including in the U.S. TECNIS PureSee^™ IOL provides excellent distance, intermediate and functional near vision.^2,3

“We are honored to receive this recognition for TECNIS PureSee^™, our latest innovation within our industry-leading portfolio of presbyopia-correcting IOLs,” said Peter Menziuso^{^}, Company Group Chairman, Vision, Johnson & Johnson. “TECNIS PureSee^™ gives surgeons and patients the choice of a premium IOL that delivers uninterrupted high-quality vision with high contrast and low-light performance, comparable to a monofocal IOL.^4,5,6,7 A huge thank you to our team for their dedication to making vision possible, and their ongoing commitment to addressing the challenging visual needs of cataract patients.”

When choosing an IOL, surgeons and patients often have to make trade-off decisions for clearer vision. For example, a patient could have a lens that offers crisp sight at all distances without spectacles, but at the price of possible glares and halos. TECNIS PureSee^™ IOL is designed to minimize these trade-offs. High levels of patient satisfaction highlight the effectiveness of the TECNIS PureSee^™ IOL, as demonstrated in multiple studies.⁸

The TECNIS PureSee^™ Toric II IOL^α is also available in select markets to treat patients with astigmatism.

## 

^* TECNIS PureSee IOL is available in EMEA, APAC, Canada, and Latin America. It has not received PMA Approval in the U.S. 

^{^} Peter Menziuso is an employee of Johnson & Johnson. 

^α TECNIS PureSee Toric II IOL has not received PMA Approval in the U.S.

^†About Vision at Johnson & Johnson 

Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients’ eyes. We have a bold ambition: Vision Made Possible – improving sight for more than 40 million people each year. Through cutting-edge innovation, expertise in material and optical science, and advanced technologies, we are revolutionizing the way people see and experience the world. Visit us at clearvisionforyou.com, follow @JNJVision on Twitter, Johnson & Johnson | Vision on LinkedIn, and @JNJVision on Facebook.

About MedTech Breakthrough Awards

The awards recognize the top companies, people, platforms and products in the health, fitness, and medical technology industries today. The mission of the Awards is to honor excellence and recognize the creativity, innovation, hard work and success of digital health and medical technology companies, services and products around the globe. This year’s program attracted more than 4,500 nominations from all over the world.

Media Contact

Janet Cheng 

Vision, Johnson & Johnson 

[email protected]


INDICATIONS and IMPORTANT SAFETY INFORMATION for TECNIS PureSee^™ IOL with TECNIS SIMPLICITY^™ Delivery System, and TECNIS PureSee^™ Toric II IOL with TECNIS SIMPLICITY^™ Delivery System

INDICATIONS FOR USE 

The TECNIS SIMPLICITY^™ Delivery System is used to fold and assist in inserting the TECNIS PureSee^™ IOL which is indicated for primary implantation for the visual correction of aphakia, in adult patients with less than 1 diopter of preexisting corneal astigmatism, in whom a cataractous lens has been removed. The lens is intended to correct presbyopia by providing improved vision over a continuous range of distances including far, intermediate, and near, and decreased spectacle dependence. The lens is intended for capsular bag placement only. 

The TECNIS SIMPLICITY^™ Delivery System is used to fold and assist in inserting the TECNIS PureSee^™ Toric II IOL which is indicated for primary implantation for the visual correction of aphakia and pre-existing corneal astigmatism in adult patients with and without presbyopia in whom a cataractous lens has been removed. The lens is intended to correct presbyopia by providing improved vision over a continuous range of distances including far, intermediate, and near, a reduction of residual refractive cylinder, and decreased spectacle dependence. The lens is intended for capsular bag placement only. 

WARNING 

Physicians should weigh the potential risk/benefit ratio of IOL implantation in patients with any of the conditions described in the Directions for Use. These conditions are not specific to the design of the IOL and are attributed to cataract surgery and/or IOL implantation in general. The IOL should be placed entirely in the capsular bag. Do not place the IOL in the ciliary sulcus. Patients should be informed of the possibility of visual disturbances. The lens may cause a reduction in contrast sensitivity under certain conditions, compared to an aspheric monofocal IOL; fully inform the patient of this risk before implanting the lens. Special consideration should be made for patients with macular disease, amblyopia, corneal irregularities, or other ocular disease. Inform patients to exercise special caution when driving at night or in poor visibility conditions.

Rotation of the TECNIS PureSee^™ Toric II IOL away from their intended axis can reduce their astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder. If necessary, IOL repositioning should occur as early as possible prior to lens encapsulation.

Do not attempt to disassemble, modify, or alter the delivery system, or any of its components, as this can significantly affect the function and/or structural integrity of the design. Do not use if the cartridge tip is cracked or split. Do not implant the IOL if the rod tip does not advance the IOL or if it is jammed in the delivery system. Do not advance the IOL from the Holding Position (located at the half turn rotation position for the initial advancement of the IOL into the cartridge) prior to fully hydrating the system and ready for implantation. A minimum of 1 minute at the Holding Position is required to fully hydrate the system to prevent sticking and a potential scratch or crack to the IOL. Interruptions during delivery may result in the IOL being scratched or cracked or stuck in the cartridge. Discard the device if the IOL has been advanced past the Holding Position but not delivered within 60 seconds. The IOL and delivery system should be discarded if the IOL has been folded within the cartridge for more than 10 minutes. Not doing so may result in the IOL being stuck in the cartridge.

PRECAUTIONS

Autorefractors may not provide optimal postoperative refraction of patients with the IOL. Manual refraction with maximum plus technique is strongly recommended. Recent contact lens usage may affect the patient’s refraction; therefore, in contact lens wearers, surgeons should establish corneal stability without contact lenses prior to determining IOL power. Target emmetropia for optimum visual performance.

For the TECNIS PureSee^™ Toric II IOL, variability in any preoperative surgical parameters (e.g., keratometric cylinder, incision location, estimated surgically induced astigmatism, or biometry) can influence patient outcomes. Carefully remove all viscoelastic and do not over-inflate the capsular bag at the end of the case, to avoid lens rotation.

This is a single use device, do not resterilize the lens or the delivery system. Do not store the device in direct sunlight or at a temperature under 5°C (41°F) or over 35°C (95°F). Do not autoclave the delivery system. Do not advance the lens unless ready for lens implantation. The contents are sterile unless the package is opened or damaged. The recommended temperature for implanting the lens is at least 17°C (63°F). The use of balanced salt solution or viscoelastics is required when using the delivery system. Do not use if the delivery system has been dropped or if any part was inadvertently struck while outside the shipping box.

ADVERSE EVENTS

Potential adverse events during or following cataract surgery with implantation of the IOL may include but are not limited to: Endophthalmitis/intraocular infection, IOL dislocation, persistent cystoid macular edema, persistent corneal stromal edema, persistent raised intraocular pressure (IOP) requiring treatment, secondary surgical intervention (including implant repositioning, removal, AC tap, or other surgical procedure). Adverse events can lead to permanent visual impairment and may require secondary surgical intervention, including intraocular lens exchange or explanation.

ATTENTION

Reference the Directions for Use for a complete listing of Indications and Important Safety Information.

^© Johnson & Johnson and its affiliates 2025